Progenity Receives Funding from Crohn’s & Colitis Foundation IBD Ventures Fund to Develop Drug Delivery System for IBD
May 11, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Positive Signals for Endoscopic and Histologic Response in Patients with Crohn’s Disease Treated with Qu Biologics’ QBECO
January 04, 2021 09:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin
February 13, 2020 10:00 ET
|
Innovation Pharmaceuticals Inc.
Targeted colonic delivery shownDrug well-tolerated WAKEFIELD, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical...
Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease
December 18, 2019 17:35 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform...
Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease
July 23, 2019 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Helmsley Charitable Trust Grants $4.3 Million to Develop Tools for the Clinical Testing of Anti-fibrotic Treatments for Crohn’s Disease Patients
April 15, 2019 12:32 ET
|
The Leona M. and Harry B. Helmsley Charitable Trust
New York, NY, April 15, 2019 (GLOBE NEWSWIRE) -- The Leona M. and Harry B. Helmsley Charitable Trust has awarded $4.3 million to Cleveland Clinic, Mayo Clinic, and Robarts Clinical Trials, Inc. to...
First stage of Qu Biologics’ clinical trial assessing mucosal healing for novel immunotherapy for Crohn’s disease reaches 50% enrolment
November 13, 2018 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018
October 22, 2018 09:26 ET
|
RedHill Biopharma Ltd.
The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of clinical remission at week 26 (p=0.007) and key secondary and other efficacy...
RedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn’s Disease Study with RHB-104 to be Presented at UEG Week 2018
October 10, 2018 07:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 10, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
Kenneth Rainin Foundation Awards $2.6 Million for Cutting-Edge IBD Research
October 02, 2018 08:00 ET
|
Kenneth Rainin Foundation
Oakland, California, Oct. 02, 2018 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation has awarded $2.6 million through its Innovator Awards program to improve the prediction and prevention of...